Leading CDMO streamlining quality management to accelerate the availability of new medicines
NEW DELHI, June 22, 2023 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that fast-growing contract development and manufacturing organization (CDMO) Anthem Biosciences has selected Veeva Vault Quality Suite as the digital foundation to drive quality excellence across its research and manufacturing facilities. With Vault Quality Suite, Anthem Biosciences will have connected systems that can simplify quality, content, and training management
“Veeva was the only solution to bring together quality content, data, and processes to support all of our manufacturing operations,” said Ravi Kalla, Anthem Biosciences chief information officer. “Veeva Vault Quality Suite will help us deliver real-time visibility to clients, increase operational efficiency, and achieve GxP compliance.”
Anthem Biosciences is a contract research and innovation service provider (CRISP) with a capacity for over 1000 researchers for the manufacture of novel commercial drugs. Anthem is adopting Veeva Vault QMS, Vault QualityDocs, and Vault Training for greater visibility and insights into operational efficiency across its biological- and chemistry-based products and services. Using applications on a single platform will enable easier collaboration with stakeholders while delivering transparency to Anthem’s customers, auditors, and regulatory agencies.
“We’re excited to partner with Anthem Biosciences and support their digital quality transformation,” said Varadarjan Srinivasan, general manager, Veeva Vault Quality India. “Veeva Vault Quality Suite will deliver a connected quality foundation to streamline processes and speed time to market for potentially life-changing medicines.”
The Veeva Vault Quality Suite includes Veeva Vault QualityDocs, Veeva Vault QMS, Veeva Vault Training, Veeva Vault Validation Management, Veeva Vault LIMS, and Veeva LearnGxP to automate and harmonize quality processes globally.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/ap
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 37 and 38), and in our subsequent SEC filings, which you can access at sec.gov.
SOURCE Veeva Systems